FDA Approves First Fecal Matter Therapy + PureTech Reveals New CBD Oral Capsule – Xtalks Life Science Podcast Ep. 89

In this episode, Ayesha talked about the FDA approval of Ferring Pharmaceuticals’ fecal matter-based therapy Rebyota for the treatment of recurrent C. difficile infections. While fecal matter transplants (FMT) have been a standard of care for recurrent CDIs, despite not having formal approval, Rebyota has become the first FDA approved FMT-based treatment for CDIs. Hear more about the drug and its approval in this episode.

Ayesha also discussed a new CBD oral capsule being developed by PureTech Health for the treatment of epilepsy and potentially other indications as well. The drug will be going up against Jazz Pharma’s Epidiolex, which was first approved in 2018 for the treatment of seizures associated with rare types of epilepsy. Hear about the advantages of an oral capsule formulation of CBD, including lower costs and not requiring the use of sesame oil.

Read the full articles here:

FDA Approves Rebyota as First Fecal Microbiome Therapy for Recurrent C. Difficile Infection

PureTech Reveals New CBD Pill to Rival Jazz’s Epidiolex

The weekly podcast is available for streaming every Wednesday on Spotify, Apple Music and wherever you stream your podcasts.

Subscribe to the Xtalks Life Science Podcast to never miss a new episode.